Angiotensin-receptor blockers, type 2 diabetes, and renoprotection.
Walser
Mackenzie
M
D057911:Angiotensin Receptor Antagonists; D000806:Angiotensin-Converting Enzyme Inhibitors / Q000009:adverse effects; D000959:Antihypertensive Agents / Q000009:adverse effects*; D001713:Biphenyl Compounds / Q000009:adverse effects*; D003924:Diabetes Mellitus, Type 2 / Q000150:complications*; D003928:Diabetic Nephropathies / Q000188:drug therapy*; D006801:Humans; D006947:Hyperkalemia / Q000139:chemically induced*; D000077405:Irbesartan; D007676:Kidney Failure, Chronic / Q000517:prevention & control*; D019808:Losartan / Q000009:adverse effects; D013777:Tetrazoles / Q000009:adverse effects*
D057911:Angiotensin Receptor Antagonists; D000806:Angiotensin-Converting Enzyme Inhibitors; D000959:Antihypertensive Agents; D001713:Biphenyl Compounds; D013777:Tetrazoles; D000077405:Irbesartan; D019808:Losartan